Avantor Inc
AVTR
ISIN null / Valor 46393297
Avantor Inc
UMushroom community rating:
About company
Avantor Inc. is a global provider of mission-critical products and services for professionals in the life sciences and advanced technology industries. The company plays a pivotal role in supporting scientific research and development across various sectors, including medicine, healthcare, and technology. Avantor's offerings encompass a broad range of reliable products, digital solutions, and innovative manufacturing facilities designed to meet the rigorous demands of its clientele. By leveraging its expertise in these areas, Avantor aims to facilitate significant advancements and breakthroughs, enabling its partners to transform life-changing possibilities into tangible realities. The company's commitment to delivering high-quality solutions underscores its integral position within the scientific community, where it serves as a key enabler of progress and innovation.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (11.11.2025):
In the second fiscal quarter of 2025, Avantor Inc reported a mixed set of results with net sales of $1.68 billion — a 1% decline year-over-year — while organic revenue remained flat. The company achieved a net income of $65 million and an adjusted EBITDA of $280 million, with both its Laboratory Solutions and Bioscience Production segments showing distinct performance trends amid operational improvements and challenges. Additionally, Avantor generated solid operating cash flow of $154 million and free cash flow of $125 million, and the company also announced a leadership transition with Emmanuel Ligner set to assume the CEO role in mid-August 2025.
Key Revenue & Profit Metrics
Net sales for Q2 2025 were $1.68 billion, reflecting a 1% decline, while organic revenue was flat. Net income decreased to $64.7 million from $92.9 million a year ago, with adjusted net income at $161.2 million, and adjusted EBITDA of $280 million supported margins at 16.6%.
Segment Performance
The Laboratory Solutions segment posted net sales of $1,122.1 million, a reported 3% decrease (or 1% organically), with adjusted operating income falling to $133.3 million. In contrast, the Bioscience Production segment saw net sales increase to $561.3 million, reflecting a 3% reported growth (or 2% organically), despite facing challenges such as planned maintenance and certain regulatory hurdles.
Cash Flow and Operational Efficiency
Operating cash flow reached $154 million and free cash flow was $125 million, underscoring the strength of Avantor’s disciplined approach to cash management and operational leverage during this quarter.
Strategic Initiatives & Leadership Transition
During the quarter, the company continued to focus on operational excellence with initiatives in both segments, including contract extensions with leading pharma companies. Additionally, Avantor announced a forthcoming CEO transition, with life-sciences veteran Emmanuel Ligner scheduled to take over as President and CEO effective August 18, 2025.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
7548 M
Market cap (USD)
10,558,796
Daily traded volume (Shares)
21.28 / 20.87
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
